Upstream Bio, Inc. (NASDAQ: UPB) is a Healthcare company (Biotechnology) with a market capitalization of $115M. The Maz Rating grades it against the other companies in its sector.
Upstream Bio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.10, Upstream Bio, Inc. trades at 39.4x sales and 0.5x book value. Over the last twelve months it generated about $3M of revenue and a net loss of $168M. It runs a gross margin of 98.3%, an operating margin of -6116.0% and a net margin of -5712.3%. It shows return on equity of -57.1%, return on invested capital of -74.8% and a free cash flow yield of -146.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 20.45. Over the past 52 weeks the share price ranged from $2.00 to $33.68, with a beta of 1.39.
Upstream Bio, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 3 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Upstream Bio, Inc. (UPB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 80.5% / 30% · Interest income / Revenue 564.6% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 80.5% / 33% · Receivables / Mkt Cap (36m) 0.57% / 49% · Interest income / Revenue 564.6% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 80.5% / 33.33% · Receivables / Mkt Cap (24m) 0.57% / 33.33% · Interest income / Revenue 564.6% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.28% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 92.1% / 33.33% · Receivables / Avg Assets (4Q) 0.44% / 33.33% · Interest income / Revenue 564.6% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 84.3% / 33.33% · (Cash+Recv) / Total Assets 84.9% / 33.33% · Interest income / Revenue 564.6% / 5% | Fail |
No. As of September 2026, Upstream Bio, Inc. (UPB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Upstream Bio, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 564.6% of each dividend: Upstream Bio, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.